Triumvira is a clinical stage immunotherapy company with the vision of developing novel T-cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T-cell receptor (TCR) therapies.

Triumvira Immunologics is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease.

Triumvira Immunologics was co-founded in 2015 by Jonathan Bramson and Christopher Helsen. The company is headquartered in Austin, Texas, with an office in Ontario, Canada. 

Triumvira's proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies.

Triumvira's lead program, TAC01-HER2, is currently being evaluated in a Phase 1/2 clinical trial for patients with HER2-overexpressing solid tumors (TACTIC-2), including breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers.

Triumvira is backed by Leaps by Bayer, B Capital Group, Northpond Ventures, Bloom Burton & Co., Oceanpine Capital, Viva Biotech Holdings, ATEM Capital, Myeloma Investment Fund, and others. The company closed a Series A extension round of an undisclosed on Mar 21, 2022. This brings Triumvira's total funding to $100M to date.